Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® regarding the emergence of cabozantinib (Cabometyx) as a treatment option for patients with renal cell carcinoma and discussed future research around the drug from an abstract on the SWOG 1500 trial (NCT02761057) at the 2021 Genitourinary Cancers Symposium.

Transcription:

From here on out, it’s going to be the infrequent patient that receives sunitinib (Sutent) in the frontline setting, outside of perhaps clinical trials. I think that cabozantinib probably should be the gold standard. The big question that emerges is ‘do we combine cabozantinib with immunotherapy now that we can do that for these patients,’ and I would suggest some pause. I would suggest that perhaps it’s better for us to wait until we have randomized data. To that end, we are moving forward with a clinical trial of cabozantinib plus or minus immunotherapy in patients with papillary kidney cancer within the cooperative groups. Once again, it’s a trial…looking at that combination of agents.

Reference:

Pal SK, Tangen C, Thompson IM, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Presented at: 2021 Genitourinary Cancers Symposium. Abstract 270.

Related Videos
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.
Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.
According to an expert from University Hospitals, oncologists should work together and look for opportunities to improve patients’ diets and exercise routines to mitigate symptoms of kidney cancer and associated treatment.
According to an expert from University Hospitals, studying pathways related to inflammation, epigenetics, and the microbiome may elucidate how patients with kidney cancer respond to anti-cancer therapy.